Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b

MLA

Mircea Manuc, et al. “Efficacy of Treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 Weeks in Chronic HCV Hepatitis Genotype 1b.” Romanian Journal of Infectious Diseases, vol. 24, no. 1, Mar. 2021, pp. 44–50. EBSCOhost, https://doi.org/10.37897/RJID.2021.1.6.

APA

Mircea Manuc, Carmen Monica Preda, Laura Iliescu, Doina Istratescu, Andreea Elena Chifulescu, Corina Silvia Pop, Anca Trifan, Carol Stanciu, Corneliu Petru Popescu, Mircea-Mihai Diculescu, Teodora Manuc, Letitia Tugui, Elena Cianga, Cristian George Tieranu, Tudor Stroie, & Liliana Simona Gheorghe. (2021). Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b. Romanian Journal of Infectious Diseases, 24(1), 44–50. https://doi.org/10.37897/RJID.2021.1.6

Chicago

Mircea Manuc, Carmen Monica Preda, Laura Iliescu, Doina Istratescu, Andreea Elena Chifulescu, Corina Silvia Pop, Anca Trifan, et al. 2021. “Efficacy of Treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 Weeks in Chronic HCV Hepatitis Genotype 1b.” Romanian Journal of Infectious Diseases 24 (1): 44–50. doi:10.37897/RJID.2021.1.6.